Pfizer (PFE) has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, a global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1, or GLP-1, receptor agonist currently in Phase 1 development for chronic weight management. YaoPharma will complete an ongoing YP05002 Phase 1 clinical trial and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide. YaoPharma will receive an upfront payment of $150M and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935B, as well as tiered royalties on sales, if approved. Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor antagonist PF-07976016 currently in Phase 2 development and with other small molecules in its pipeline.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Mixed options sentiment in Pfizer with shares up 0.13%
- Can Life Wave Sciences Disrupt the Obesity Market? WVE Soars 147% after Initial Results
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Eli Lilly, Pfizer, Johnson secure spots on China’s drug catalog, Bloomberg says
- Pfizer presents results from the Phase 3 BASIS study on HYMPAVZI